Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898837 | 0.81 | CHRM1 (0.41) | ALDH1A1TP53TSHR | |
| SCHEMBL3369505 | 0.78 | CA2 (0.42) | — | |
| SCHEMBL16969946 | 0.77 | — | — | |
| SCHEMBL3368465 | 0.76 | GPR84 (0.44) | — | |
| SCHEMBL7592946 | 0.75 | SLC22A6 (0.38) | LMNAALDH1A1TP53TSHR | |
| SCHEMBL31376159 | 0.75 | CA2 (0.38) | LMNAALDH1A1TP53TSHRFFAR3 | |
| SCHEMBL3368152 | 0.74 | GPR84 (0.47) | ALDH1A1TSHR | |
| SCHEMBL3371201 | 0.74 | GPR84 (0.47) | ALDH1A1TSHR | |
| SCHEMBL3368426 | 0.74 | GPR84 (0.47) | ALDH1A1TSHR | |
| SCHEMBL3368526 | 0.74 | GPR84 (0.47) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230176481-A1 | FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-06-08 | — | — | US | disclosed |
| US-9283199-B2 | Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms | CIMAS LIMITED (CY) | 2016-03-15 | — | — | US | disclosed |
| US-20160067198-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CIMAS LIMITED (CY) | 2016-03-10 | — | — | US | disclosed |
| EP-2440198-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | Mardi Medicines Ltd. (IL) | 2012-04-18 | — | — | EP | disclosed |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2011-03-03 | — | — | US | disclosed |
| WO-2010143188-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067198-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CCR10, PBK, CCR3 | LMNA 3617/4885ALDH1A1 1008/4885TP53 48/4885 |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CCR10, PBK, CCR3 | LMNA 3617/4885ALDH1A1 1008/4885TP53 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.